Clinical Trials Logo

2019-nCoV clinical trials

View clinical trials related to 2019-nCoV.

Filter by:

NCT ID: NCT04356508 Not yet recruiting - COVID-19 Clinical Trials

COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

Start date: April 14, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.

NCT ID: NCT04334967 Suspended - COVID-19 Clinical Trials

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Start date: March 30, 2020
Phase: Phase 4
Study type: Interventional

This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19

NCT ID: NCT04321928 Recruiting - COVID-19 Clinical Trials

Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary

PROACTIVE-19
Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The additional effect of personalized health education compared to general education following the internationally accepted principles will be evaluated in the prevention of the serious course of the novel coronavirus infection. It is hypothesised that personalized health education provides a greater degree of lifestyle change, thus the risk of a serious course of infection decreases.

NCT ID: NCT04273763 Active, not recruiting - 2019-nCoV Clinical Trials

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

Start date: February 16, 2020
Phase: N/A
Study type: Interventional

Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard treatment/ standard treatment in patients with suspected and mild, or common novel coronavirus pneumonia (COVID-19). Random, open, group sequential design.

NCT ID: NCT04272710 Withdrawn - 2019-nCoV Clinical Trials

Prognositc Factors in COVID-19 Patients Complicated With Hypertension

Start date: January 25, 2020
Phase:
Study type: Observational

There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

NCT ID: NCT04270383 Not yet recruiting - 2019-nCoV Clinical Trials

Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children

Start date: February 15, 2020
Phase:
Study type: Observational

The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.

NCT ID: NCT04264858 Not yet recruiting - 2019-nCoV Clinical Trials

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

Start date: March 17, 2020
Phase: N/A
Study type: Interventional

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.

NCT ID: NCT04261907 Not yet recruiting - 2019-nCoV Clinical Trials

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Start date: February 7, 2020
Phase: N/A
Study type: Interventional

Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.

NCT ID: NCT04261426 Not yet recruiting - 2019-nCoV Clinical Trials

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Start date: February 10, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.

NCT ID: NCT04260594 Not yet recruiting - 2019-nCoV Clinical Trials

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Start date: February 7, 2020
Phase: Phase 4
Study type: Interventional

In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.